Nothing Special   »   [go: up one dir, main page]

WO2024068617A1 - Cellules myéloïdes exprimant l'il-2 et leurs utilisations pour une thérapie anticancéreuse rapide - Google Patents

Cellules myéloïdes exprimant l'il-2 et leurs utilisations pour une thérapie anticancéreuse rapide Download PDF

Info

Publication number
WO2024068617A1
WO2024068617A1 PCT/EP2023/076524 EP2023076524W WO2024068617A1 WO 2024068617 A1 WO2024068617 A1 WO 2024068617A1 EP 2023076524 W EP2023076524 W EP 2023076524W WO 2024068617 A1 WO2024068617 A1 WO 2024068617A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell
cells
antigen
modified
car
Prior art date
Application number
PCT/EP2023/076524
Other languages
English (en)
Inventor
Philippe Benaroch
Jovan Nikolic
Nadia JEREMIAH
Eliane Piaggio
Christine Sedlik
Original Assignee
Institut Curie
Institut National De La Sante Et De La Recherche Medicale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Curie, Institut National De La Sante Et De La Recherche Medicale filed Critical Institut Curie
Publication of WO2024068617A1 publication Critical patent/WO2024068617A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4614—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4635—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Definitions

  • the present invention concerns a modified cell comprising a transgene coding for interleukin-2 (IL-2).
  • Said modified cell preferably modified myeloid cell, comprises a first vector comprising a sequence coding for IL-2 under the control of an inducible or constitutive promoter, which notably enables a locally contained expression of IL-2. It also relates to therapeutic uses thereof.
  • TME tumor microenvironment
  • the TME is a complex, heterogeneous mix of cellular populations that interact with one another and with the tumor cells.
  • the TME is immunosuppressive, both evading the immune system and preventing therapeutic intervention from efficiently eliminating malignant cells.
  • Myeloid cells within the TME play an important role in contributing to immune evasion by exhibiting potent immunosuppressive as well as pro-tumorigenic properties.
  • TAMs tumor-associated macrophages
  • TME tumor-associated macrophages
  • TAMs can represent a significant portion of the tumor mass, up to 50% in some breast tumors. They develop into immunosuppressive macrophages, which hinder anti-tumor CD8+ T cells from infiltrating the tumor and attract or induce regulatory T cells (T reg). TAMs secrete growth factors like VEGF or TGFp, which promote tumor growth and invasive behavior.
  • CAR Chimeric Antigen Receptor
  • the CAR-T cells may encounter physical barriers in the form of TAMs and cancer-associated fibroblasts that produce vast amounts of extracellular matrix.
  • CAR-T cells do not successfully invade the TME due to a lack of metabolic resources or signals provided by TME cell components.
  • CAR-T cells become “exhausted” or dysfunctional losing their effector function and failing to evolve into effector memory T cells.
  • Macrophages are antigen-presenting cells that can stimulate T cells locally and thus promote adaptive anti-tumor responses. Macrophages produce proteases that can dramatically modify the extracellular matrix within the tumor mass and hence the architecture of the tumor tissue. Macrophages also have anti-tumor capabilities, such as the ability to phagocyte entire tumor cells or undertake antibody-dependent cell phagocytosis. The intrinsic features of macrophages make them an ideal candidate to overcome the limitations of CAR-T cells.
  • monocytes are considered as a better candidate for cell modification due to their better ability to penetrate the tumor tissue before differentiation into macrophages.
  • IL-2 Systemic administration of IL-2 to boost the T cell responses promote anti-tumor immunity in mouse tumor models.
  • the cytokine IL-2 has pleiotropic effects activating T and NK cells.
  • systemic administration of IL-2 needs repetitive injection as IL-2 has a short half-life in vivo. These repeated injections have been shown to have deleterious effects. IL-2 has therefore been neglected in therapeutic uses, but local expression of IL-2 could be of major interest.
  • the present invention fulfills these needs.
  • the present invention thus relates to modified cell, wherein the cell is chosen from myeloid cells, induced pluripotent stem cells (iPS) and hematopoietic stem cells (HSC), and wherein the cell comprises:
  • a first vector comprising a sequence coding for at least one cytokine, preferably at least one interleukin, under the control of an inducible or constitutive promoter, and a second vector comprising a sequence coding for a chimeric antigen receptor (CAR); or
  • (ii) only comprises the first vector, which encodes for both the at least one cytokine, preferably at least one interleukin, and for the CAR.
  • the present invention thus relates to a modified cell expressing interleukin-2 (IL-2), wherein the cell is chosen from myeloid cells, induced pluripotent stem cells (iPS) and hematopoietic stem cells (HSC), and wherein the cell comprises a first vector comprising a sequence coding for IL-2 under the control of an inducible or constitutive promoter.
  • IL-2 interleukin-2
  • iPS induced pluripotent stem cells
  • HSC hematopoietic stem cells
  • the modified cell is a modified myeloid cell which comprises a first vector comprising a sequence coding for IL-2 under the control of an inducible or constitutive promoter.
  • the modified cell further comprises a second vector comprising a sequence coding for a chimeric antigen receptor (CAR).
  • CAR chimeric antigen receptor
  • the invention also relates to a modified cell expressing at least one cytokine, preferably an interleukin, wherein the cell is chosen from myeloid cells, induced pluripotent stem cells (iPS) and hematopoietic stem cells (HSC), and wherein the cell comprises a first vector comprising a sequence coding for said cytokine under the control of an inducible or constitutive promoter, and optionally a second vector comprising a sequence coding for a chimeric antigen receptor (CAR), wherein said CAR comprises:
  • TEE tumor microenvironment
  • the invention also relates to a modified cell expressing at least one interleukin chosen from IL-10, IL-15, IL-13, IL-7A, IFNalpha, IFNbeta, IFNIambda, IFNgamma, IL-1A, IL-1 B, IL-12 and IL-21 , wherein the cell is chosen from myeloid cells, induced pluripotent stem cells (iPS) and hematopoietic stem cells (HSC), and wherein the cell comprises a first vector comprising a sequence coding for said interleukin under the control of an inducible or constitutive promoter, and optionally a second vector comprising a sequence coding for a chimeric antigen receptor (CAR), wherein said CAR comprises:
  • TEE tumor microenvironment
  • the at least one cytokine is linked with a 2A peptide to another cytokine, preferably another interleukin, an antigenic polypeptide, a single chain antibody or a nanobody, which allows for ribosomal skipping during translation of a protein.
  • Said antigenic polypeptide, single chain antibody or nanobody can either block or stimulate a receptor and allow to target specific cells, preferably tumor cells or cells from the TME such as cancer-associated fibroblast (CAF), or regulatory T cells.
  • said antigenic polypeptide has a length of about 8 to about 50 amino acids.
  • the present invention also relates to a method for manufacturing a modified myeloid cell, a modified iPS or a modified HSC, the method comprising:
  • - providing at least one cell chosen from isolated myeloid cells, iPS and HSC;
  • a first vector preferably a lentiviral vector, comprising a cytokine, preferably an interleukin, under the control of an inducible or constitutive promoter, preferably under the control of the promoter of interleukin-6 or the promoter of interleukin-8; and
  • transducing said cell with a second vector preferably a lentiviral vector, comprising a nucleic sequence coding for a CAR.
  • the present invention also relates to a method for manufacturing a modified myeloid cell, a modified iPS or a modified HSC, the method comprising:
  • a first vector preferably a lentiviral vector, comprising a sequence coding for IL-2 or a sequence coding for at least one interleukin chosen from IL-10, IL-15, IL-13, IL-7A, IFNalpha, IFNbeta, IFNIambda, IFNgamma, IL-1 A, IL-1 B, IL-12 and IL-21 , under the control of an inducible or constitutive promoter, preferably under the control of the promoter of interleukin-6 or the promoter of interleukin-8; and
  • transducing said cell with a second vector preferably a lentiviral vector, comprising a nucleic sequence coding for a CAR.
  • the present invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising the modified myeloid cell, the modified iPS or the modified HSC according to the invention, and a pharmaceutical acceptable carrier.
  • the present invention also relates to the use of the modified myeloid cell, the modified iPS or the modified HSC according to the invention, or of the pharmaceutical composition, in the treatment of cancer, an autoimmune disease or an inflammatory disease.
  • the present invention further relates to products containing the modified myeloid cell, the modified iPS or the modified HSC according to the invention, and a CAR-T cell, as a combined preparation for simultaneous, separate or sequential use in treatment of cancer, an autoimmune disease or an inflammatory disease.
  • the present invention also relates to products containing the modified myeloid cell, the modified iPS or the modified HSC according to the invention, and an Immune Checkpoint Inhibitor as a combined preparation for simultaneous, separate or sequential use in treatment of cancer, an autoimmune disease or an inflammatory disease.
  • monocytes which are transduced both with a specific CAR and with the gene coding for IL- 2 under the control of a specific promoter, may be used as treatment notably in cancer therapy.
  • said monocytes are able to penetrate tumor and differentiate as IL-2 expressing macrophages able to bind a given antigen, activating thus their great capacity to phagocytose tumor cells, but also to further mobilize the antigen presentation and co- stimulatory capacities of macrophages upon their encounter of tumor cells, and thus to stimulate anti-tumor immunity.
  • the present invention relates to modified cell, wherein the cell is chosen from myeloid cells, induced pluripotent stem cells (i PS) and hematopoietic stem cells (HSC), and wherein the cell comprises:
  • a first vector comprising a sequence coding for at least one cytokine, preferably at least one interleukin, under the control of an inducible or constitutive promoter, and a second vector comprising a sequence coding for a chimeric antigen receptor (CAR); or
  • (ii) only comprises the first vector, which encodes for both the at least one cytokine, preferably at least one interleukin, and for the CAR.
  • the present invention relates to a modified myeloid cell expressing IL-2, wherein the cell comprises a first vector comprising a sequence coding for IL-2 under the control of an inducible or constitutive promoter.
  • the present invention also relates to a modified induced pluripotent stem cell (iPS) or hematopoietic stem cell (HSC) expressing interleukin-2 (IL-2), wherein the cell comprises a first vector comprising a sequence coding for IL-2 under the control of an inducible or constitutive promoter.
  • iPS modified induced pluripotent stem cell
  • HSC hematopoietic stem cell
  • IL-2 interleukin-2
  • Said cell is also called the “modified cell” in the present application.
  • myeloid cell it is meant any type of cells derived from the myeloid tissue (bone marrow), or resembling bone marrow. Preferably, it is a monocyte, a macrophage or a dendritic cell, more preferably a monocyte. Said myeloid cell is modified in that it expresses at least IL-2.
  • stem cell By “stem cell”, it is meant a cell that, by successive divisions can give rise to specialized cells.
  • the term “pluripotent stem cell” refers to a stem cell that has the potential to differentiate into any of the three germ layers: endoderm (interior stomach lining, gastrointestinal tract, the lungs), mesoderm (muscle, bone, blood, urogenital), or ectoderm (epidermal tissues and nervous system). Pluripotent stem cells can give rise to any fetal or adult cell type but they cannot give rise to an entire organism.
  • a “pluripotent stem cell” may be identified by the expression of one or more of the cell markers Klf4, Sox2, Oct4, cMyc, Nanog and SSEA1 .
  • endoderm identified by the expression of alpha-fetoprotein
  • mesoderm identified by the expression of desmin and/or alpha smooth muscle actin
  • Assays to assess the pluripotentiality of a cell are known in the art.
  • induced pluripotent stem cell or "iPS”
  • iPS a pluripotent cell artificially derived from a non-pluripotent cell, typically an adult somatic cell, by inducing a forced expression of certain genes.
  • An "induced pluripotent stem cell” is defined by the expression of several transcription factors including one or more of Klf4, Sox2, Oct4 and cMyc.
  • iPS cells are typically derived by transfection of certain stem cell-associated genes into non- pluripotent cells, such as adult fibroblasts. Transfection is typically achieved through viral vectors, such as retroviruses, and transfected genes include Oct-3/4 (Pou5fl) and Sox2.
  • Additional genes include certain members of the Klf family ( Klf I , Klf 2, Klf4 and Klf 5) , the Myc family (c-myc, L-myc, N-myc), Nanog and LIN28 have been identified to increase the induction efficiency.
  • Klf I , Klf 2, Klf4 and Klf 5 the Myc family (c-myc, L-myc, N-myc), Nanog and LIN28 have been identified to increase the induction efficiency.
  • Klf I , Klf 2, Klf4 and Klf 5 the Myc family (c-myc, L-myc, N-myc), Nanog and LIN28 have been identified to increase the induction efficiency.
  • the « hematopoietic stem cells » possess the ability to fully reconstitute the immune system of a lethally irradiated host from which the cells are obtained.
  • the hematopoietic stem cells give rise to all blood and immune cells.
  • the cell especially the myeloid cell of the HSC, is obtained from a biological sample from a donor affected by cancer, an autoimmune disease or an inflammatory disease.
  • First vector coding for at least one cytokine, preferably at least one interleukin, preferably with IL-2 lnterleukin-2 (IL-2) is the interleukin that induces the proliferation of responsive T cells and NK cells.
  • IL-2 enhances activation-induced cell death (AICD).
  • AICD activation-induced cell death
  • IL-2 also promotes the differentiation of T cells into effector T cells and into memory T cells when the initial T cell is also stimulated by an antigen, thus helping the body fight off infections.
  • IL-2 stimulates naive CD4+ T cell differentiation into Th1 and Th2 lymphocytes while it impedes differentiation into Th17 and folicular Th lymphocytes.
  • IL- 2 increases also the cell killing activity of both natural killer cells and cytotoxic T cells.
  • IL-2 is human IL-2 (h IL-2).
  • IL-2 is encoded by the following nucleic sequence:
  • IL-2 is encoded by the following amino acid sequence:
  • the first vector of the modified myeloid cell, the modified iPS or the modified HSC according to the invention comprises a sequence coding for IL-2 under the control of an inducible or constitutive promoter.
  • the sequence coding for IL-2 is inserted in a lentivector, preferably pCDH1 , optionally containing a resistance gene, and under control of an inducible or constitutive promoter.
  • the promoter is inducible.
  • Constitutive or inducible promoters are usually associated with constitutive or inducible genes, respectively.
  • a constitutive gene is a gene that is permanently transcribed, as opposed to a facultative gene.
  • An inducible gene is a gene whose expression responds to a stimulus, such as an environmental change or the position in the cell cycle. An inducible gene is inactive unless there is the presence of an inducer that allows the gene to be expressed.
  • the use of such constitutive or inducible promoters in genetic engineering allows the regulation of the transduced genes of interest to be controlled. Inducible promoters are generally preferred over constitutive promoters for their reversibility and flexibility.
  • inducible promoters are generally more efficient and have fewer side effects, such as cell death and delayed growth or development.
  • the constitutive promoter is the immediate early cytomegalovirus (CMV) promoter sequence.
  • CMV immediate early cytomegalovirus
  • This promoter sequence is a strong constitutive promoter sequence capable of driving high levels of expression of any polynucleotide sequence operatively linked thereto.
  • constitutive promoter sequences may also be used, such as the simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV), human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter, MoMuLV promoter, an avian leukemia virus promoter, an Epstein-Barr virus immediate early promoter, a Rous sarcoma virus promoter, the actin promoter, the myosin promoter, the hemoglobin promoter and the creatine kinase promoter.
  • SV40 simian virus 40
  • MMTV mouse mammary tumor virus
  • HSV human immunodeficiency virus
  • LTR long terminal repeat
  • MoMuLV promoter MoMuLV promoter
  • an avian leukemia virus promoter an Epstein-Barr virus immediate early promoter
  • Rous sarcoma virus promoter the actin promoter
  • the myosin promoter the hemoglobin promoter
  • the first vector comprises an inducible promoter.
  • said inducible promoter is specific, i.e. it activates transcription mainly in response to CAR activation.
  • An inducible promoter provides a molecular switch capable of turning on expression of the polynucleotide sequence which it is operatively linked when such expression is desired, or turning off the expression when expression is not desired. Inducible promoters are well- known in the art.
  • the inducible promoter is chosen from positive and negative inducible promoters.
  • the activator protein binds to the promoter to initiate transcription.
  • the promoter is inactive, because a bound repressor protein actively prevents transcription. Once an inducer binds to the repressor protein, said repressor protein is removed from the DNA, and transcription can be activated.
  • the inducible promoter can be activated in response to a stimulus, such as the presence or absence and/or the amount of a chemical agent, or a change of temperature and/or light.
  • Chemically regulated promoters are among the most common inducible promoters.
  • the inducible positive tetracycline ON (Tet-On) system works by direct activation.
  • the tetracycline-controlled reverse transactivator (rtTA) is normally inactive and cannot bind to tetracycline response elements (TREs) in a promoter.
  • Tetracycline and its derivatives are used as inducing agents to enable promoter activation.
  • the inducible promoter may also be a promoter inducible by a chemical agent whose administration would be controlled over time or even locally.
  • the administered chemical agent can be chosen from a wide possibility of molecules, such as tetracycline, biotin or the combination Tet-Off/Tet-On. The possibility of using photoimmunotherapy would also allow a localized and limited time action.
  • Cytokine specific promoters are also known; they are activated once the cytokine binds to the promoter.
  • the cytokine specific promoter is the promoter of interleukin-6 or the promoter of interleukin-8.
  • negative inducible promoter pLac examples include the negative inducible promoter pBad.
  • Some promoters are temperature inducible. They show almost no expression at normal temperatures but can be induced by exposure to heat or cold. For example, the Hsp70 promoter is inducible by heat shock.
  • Light is another means of activating gene expression, and two-component systems used in synthetic biology use light to regulate transcription.
  • a light-sensitive protein such as YF1 (known as Histidine Kinase), that is capable of inducing a transcriptional response, including acting on the synthesis of a repressor or an inducer.
  • the inducible promoter is chosen from chemically regulated promoters, temperature inducible promoters and light inducible promoters.
  • the inducible promoter is chosen from cytokine specific promoters (more preferably from the promoter of interleukin-6 and the promoter of interleukin-8), metallothionine promoters, glucocorticoid promoters, progesterone promoters, tetracycline promoters (such as Tet-On promoter), pLac, pBad, heat shock protein promoters (more preferably Hsp70 promoter) and YF1.
  • the inducible promoter may also be chosen from artificial promoters containing response elements that are activated via the activation of the CAR.
  • Artificial promoters may be designed from minimal promoters complemented with multiple binding sites for transcription factors such as NF-KB, AP1 or ISRE (IFN-sensitive response element).
  • the artificial promoter comprises at least ISRE.
  • the artificial promoter is a mouse INFbeta promoter (that comprises ISRE), a promoter complemented with NF- KB responsive elements, or a combination thereof.
  • the promoter may also be promX, of SEQ ID NO: 13.
  • a preferred inducible promoter is a cytokine specific promoter (more preferably the promoter of interleukin-6 or the promoter of interleukin-8 or the promoter of interferon beta) which comprises response elements (i.e. binding sequences) to NF-KB or ISRE, or both.
  • the inducible promoter is promX of SEQ ID NO: 12 or a cytokinespecific promoter which comprises response elements to NF-KB or ISRE, preferably the inducible promoter is promX of SEQ ID NO: 13 or the promoter NF-KB of SEQ ID NO:14.
  • Said inducible promoter is preferably activated by the tumor environment around the IL-2 expressing cell.
  • the inducible promoter is a cytokine specific promoter.
  • the cytokine specific promoter is the promoter of interleukin-6 or the promoter of interleukin-8 or a synthetic promoter containing various elements able to bind transcription factors.
  • the inducible promoter is typically activated once the modified cell reaches the tumor.
  • the sequence coding for IL-2 is inserted in a lentivector, preferably pCDH1 , under control of a constitutive promoter.
  • a lentivector preferably pCDH1
  • This alternative does not allow the control of IL-2 expression.
  • the sequence coding for IL-2 is inserted in a lentivector, preferably pCDH1 , under control of an inducible promoter.
  • the invention also relates to a modified cell expressing at least one cytokine, preferably at least one interleukin chosen from IL-10, IL-15, IL-13, IL-7A, IFNalpha, IFNbeta, IFNIambda, IFNgamma, IL-1 A, IL-1 B, IL-12 and IL-21 , wherein the cell is chosen from myeloid cells, induced pluripotent stem cells (iPS) and hematopoietic stem cells (HSC), and wherein the cell comprises a first vector comprising a sequence coding for said interleukin under the control of an inducible or constitutive promoter, and optionally a second vector comprising a sequence coding for a chimeric antigen receptor (CAR), wherein said CAR comprises:
  • TEE tumor microenvironment
  • All the above embodiments for the first vector are also applicable to said modified cell expressing a cytokine.
  • the sequence of the cytokine to be expressed is introduced into the first vector instead of the sequence coding for IL-2.
  • the modified myeloid cell, iPS or HSC according to the invention comprises a first vector comprising a sequence coding for IL-2 under the control of an inducible or constitutive promoter, and further a second vector comprising a sequence coding for a chimeric antigen receptor (CAR), wherein said CAR comprises:
  • TEE tumor microenvironment
  • Such a cell is able to bind to tumor antigen or an antigen present on cells of the tumor microenvironment and typically presents a targeted effector activity such as an antigendependent phagocytosis of tumor cells.
  • the modified myeloid cell, the modified iPS or the modified HSC of the invention preferably further comprises a second vector comprising a sequence coding for a chimeric antigen receptor (CAR).
  • CAR chimeric antigen receptor
  • the CAR with its promoter can be included in the first vector (i.e. the vector comprising at least one interleukin sequence).
  • the modified myeloid cell, the modified iPS or the modified HSC of the invention only comprises the first vector, which encodes both for the interleukin and for the CAR; said vector is called “CAR2bands”.
  • the CAR with its promoter can be upstream or downstream the at least one interleukin sequence.
  • the CAR with its promoter is downstream the at least one interleukin sequence.
  • the CAR with its promoter is downstream the IL2 sequence.
  • the CAR2bands vector comprises the nucleic acid sequence SEQ ID NO:9.
  • the modified myeloid cell, iPS or HSC comprises a first vector (“CAR2bands”) comprising a sequence coding for IL-2 under the control of an inducible or constitutive promoter, and a sequence coding for a chimeric antigen receptor (CAR) under the control of an inducible or constitutive promoter, wherein said CAR comprises: an extracellular antigen-binding domain which binds to a tumor antigen or an antigen present on cells of the tumor microenvironment (TME); - optionally a hinge domain;
  • CAR2bands comprising a sequence coding for IL-2 under the control of an inducible or constitutive promoter
  • CAR chimeric antigen receptor
  • the CAR2bands comprises the CAR with its promoter downstream the sequence coding for IL-2 under the control of an inducible or constitutive promoter.
  • the CAR2bands comprises the CAR with its promoter in 3’ of the sequence coding for IL-2 under the control of an inducible or constitutive promoter.
  • the CAR of the invention comprises, from its N-terminal end to its C-terminal end:
  • a linker identical or different, may be present between each domain.
  • the CAR does not comprise any linker between the different domains.
  • the CAR is obtained by direct fusion of the different domains.
  • antigen-binding domain any polypeptide or fragment thereof, such as an antibody fragment variable domain, either naturally-derived or synthetic, which binds to an antigen.
  • Antigen-binding domains notably include polypeptides derived from antibodies, such as single chain variable fragments (scFv), Fab, Fab', F(ab')2, Fv fragments and nanobodies; polypeptides derived from T cell receptors (TCR), such as TCR variable domains; and any ligand or receptor fragment that binds to the antigen.
  • Said antigen-binding domain has antigen specificity for a tumor antigen or a TME antigen.
  • An « antigen-binding domain which has antigen specificity for a tumor antigen” is an antigen-binding domain that binds to an antigen on a tumor.
  • An « antigen-binding domain which has antigen specificity for a TME antigen” is an antigen-binding domain that binds to an antigen which is present on cells of the tumor microenvironement (TME).
  • TME tumor microenvironement
  • the TME includes the tissues and cells around a tumor; it notably includes the surrounding blood vessels, immune cells such as Treg cells or immunosuppressive macrophages, fibroblasts, signaling molecules and the extracellular matrix.
  • the tumor antigen is chosen from antigens expressed at the surface of tumor cells at higher levels than on other cell types.
  • the tumor antigen is chosen from CD19, MUC16, MUC1 , CA1X, carcinoembryonic antigen (CEA), CD8, CD7, CD 10, CD20, CD22, CD30, CLL1 , CD33, CD34, CD38, CD41 , CD44, CD49f, CD56, CD74, CD133, CD138, EGP-2, EGP-40, EpCAM, erb-B2,3,4, FBP, Fetal acetylcholine receptor, folate receptor-a, GD2, GD2Ac, GD3, ITER-2, hTERT, IL-l3R-a2, K-light chain, KDR, LeY, LI cell adhesion molecule, MAGE-A1 , Mesothelin, ERBB2, MAGEA3, p53, MARTI, GPI00, Proteinase 3 (PR1 ), Tyros
  • the TME antigen is chosen from antigens expressed by activated CAF such as FAP (Fibroblast Activation Protein), antigens expressed by T regs and antigens expressed by protumoral myeloid cells such as TREM-2.
  • FAP Fibroblast Activation Protein
  • the TME antigen is chosen from FAP, antigens expressed by Tregs and TREM-2.
  • the tumor antigen or TME antigen is CD19. More preferably, the extracellular antigen-binding domain which binds to a tumor antigen or a TME antigen is an anti-CD19 binding domain, preferably an anti-CD19 scFV.
  • the extracellular antigen-binding domain comprises the amino acid sequence:
  • hinge domain any hinge domain present in immunoglobulins or in CD molecules.
  • the hinge domain is the one of CD8.
  • CD8 comprises an alpha chain (CD8a) and a beta chain (CD8b).
  • CD8a alpha chain
  • CD8b beta chain
  • the hinge domain is the one of the CD8a chain.
  • CD8a The human version of CD8a may be found in Uniprot under accession number Q8TAW8.
  • CD8a comprises 235 amino acids.
  • the hinge domain is the fragment of amino acids 138 to 182 of said sequence, which corresponds to SEQ ID NO:4.
  • the hinge domain is the one of CD8a, preferably of human CD8a.
  • the hinge domain comprises the amino acid sequence TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD (SEQ ID NO:4).
  • transmembrane domain it is meant a single-pass or a multipass transmembrane sequence.
  • Single-pass transmembrane regions are found in certain CD molecules, tyrosine kinase receptors, serine/threonine kinase receptors, TGF, BMP, activin and phosphatases.
  • Single-pass transmembrane regions often include a signal peptide region and a transmembrane region of about 20 to about 25 amino acids, many of which are hydrophobic amino acids and can form an alpha helix.
  • a short track of positively charged amino acids often follows the transmembrane span to anchor the protein in the membrane.
  • Multipass transmembrane domains are present in proteins such as ion pumps, ion channels and transporters, and include two or more helices that span the membrane multiple times.
  • Sequences for single-pass and multipass transmembrane domains are known and can be selected for incorporation into the CAR.
  • the transmembrane domain can be chosen from wild-type transmembrane domains and mutated transmembrane domains. Mutated transmembrane domains may be modified by a mutation, such as an amino acid substitution (for example, an amino acid which is typically charged is substituted by a hydrophobic residue).
  • the transmembrane domain is the one of the alpha, beta or zeta chain of the T cell receptor, CD3-8, CD3zeta, CD4, CD5, CD8, CD8a, CD9, CD16, CD22, CD28, CD33, CD38, CD64, CD80, CD86, CD134, CD137 or CD154.
  • the transmembrane domain is a CD8 transmembrane domain.
  • the transmembrane domain may also be synthesized de novo, comprising mostly hydrophobic residues, such as, for example, leucine and valine.
  • the transmembrane domain is fused at its N-terminal end to the extracellular antigen-binding domain of the CAR, and at its C-terminal end to the intracellular signaling domain.
  • a short polypeptide linker may form the linkage between the transmembrane domain and the intracellular signaling domain of the CAR.
  • the CAR may further comprise a stalk, that is, an extracellular region of amino acids between the extracellular antigen-binding domain and the transmembrane domain.
  • the stalk may be a sequence of amino acids naturally associated with the selected transmembrane domain.
  • the CAR comprises a CD8 transmembrane domain.
  • the CAR comprises a CD8 transmembrane domain, and a CD8 hinge domain. Said hinge domain is preferably fused (preferably directly), at its C-terminal end, to the N-terminal end of the transmembrane domain.
  • the transmembrane domain comprises the amino acid sequence IYIWAPLAGTCGVLLLSLVITLYC (SEQ ID NO:5).
  • This transmembrane domain is the one of human CD8.
  • the hinge domain comprises the amino acid sequence TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD (SEQ ID NO:4).
  • intracellular domain an intracellular signaling domain at the C-terminal end of the CAR. This intracellular domain can be chosen depending on the targeted effector activity aimed by the CAR.
  • the intracellular domain can be derived from other receptors and can be designed to elicit a given cell function, such as phagocytosis, inflammatory activation or TME modulation.
  • the intracellular domain can comprise one or more intracellular signaling domains derived from a phagocytic receptor, a scavenger receptor or an integrin receptor.
  • the intracellular domain can comprise one or more intracellular signaling domains that promote phagocytic activity, an inflammatory response or integrin activation.
  • the intracellular signaling domain may be derived from a phagocytic or tethering receptor or may comprise a phagocytosis activation domain.
  • the intracellular signaling domain that promote phagocytic activity i.e. also called phagocytosis activation domain
  • the intracellular signaling domain is derived from a receptor other than a phagocytic receptor selected from Megfl O, MerTk, FcR-alpha or Bail .
  • the intracellular signaling domain is derived from a phagocytic receptor chosen from lectin, dectin 1 , CD206, scavenger receptor A1 (SRA1 ), MARCO, CD36, CD163, MSR1 , SCARA3, COLEC12, SCARA5, SCARB1 , SCARB2, CD68, OLR1 , SCARF1 , SCARF2, CXCL16, STAB1 , STAB2, SRCRB4D, SSC5D, CD205, CD207, CD209, RAGE, CD14, CD64, F4/80, CCR2, CX3CR1 , CSF1 R, Tie2, HuCRIg(L), CD64, CD32a, CD16a, CD89, Fc-alpha receptor I, CR1 , CD35, CR3, CR4, Tim-1 , Tim-4 and Preferably, the intracellular signaling domains that promote an inflammatory response (i.e.
  • proinflammatory signaling domain comprises a PI3-kinase (PI3K) recruitment domain.
  • PI3K PI3-kinase
  • it comprises an intracellular signaling domain of TLR3, TLR4, TLR9, MYD88, TRIF, RIG-1 , MDA5, IFN receptor, NLRP-1 , NLRP-2, NLRP-3, NLRP- 4, NLRP-5, NLRP-6, NLRP-7, NLRP-8, NLRP-9, NLRP-10, NLRP-11 , NLRP-12, NLRP-13, NLRP-14, NOD1 , NOD2, Pyrin, AIM2, NLRC4 and/or CD40.
  • TLR3, TLR4, TLR9, MYD88, TRIF RIG-1 , MDA5, IFN receptor, NLRP-1 , NLRP-2, NLRP-3, NLRP- 4, NLRP-5, NLRP-6, NLRP-7, NLRP-8, NLRP-9
  • the intracellular domain comprises at least two intracellular signaling domains, which comprise: either (i) a first intracellular signaling domain derived from FcyR or FCER, and (ii) a second intracellular signaling domain: (A) comprising a PI3K recruitment domain, or (B) derived from CD40; or (i) a first intracellular signaling domain derived from a phagocytic receptor, and (ii) a second intracellular signaling domain: (A) comprising a PI3K recruitment domain, or (B) derived from CD40.
  • intracellular signaling domains comprise: either (i) a first intracellular signaling domain derived from FcyR or FCER, and (ii) a second intracellular signaling domain: (A) comprising a PI3K recruitment domain, or (B) derived from CD40; or (i) a first intracellular signaling domain derived from a phagocytic receptor, and (ii) a second intracellular signaling domain: (A
  • intracellular domain examples include a fragment or domain from one or more molecules or receptors including, but are not limited to, STING, cGAS, TCR, CD3 zeta, CD3 gamma, CD3 delta, CD3 epsilon, CD86, CD79a, CD79b, DAP10, DAP 12, T cell receptor (TCR), CD27, CD28, 4-1 BB (CD137), 0X40, CD30, CD40, PD-1 , ICOS, lymphocyte function-associated antigen-1 (LFA-1 ), CD2, CD7, LIGHT, NKG2C, B7-H3, a ligand that specifically binds with CD83, CDS, ICAM-1 , GITR, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1 ), CD127, CD160, CD19, CD4, CD8alpha, CD8beta, IL-2R beta, IL-2R gamma, IL-7R alpha,
  • the intracellular signaling domain of the invention comprises, from N- terminal to C-terminal, a first intracellular signaling domain comprising the CD40 cytotail (cytoplasmic tail), which is fused to a second intracellular signaling domain comprising the CD3zeta intracellular domain.
  • CD40 cytotai I it is meant the cytosolic domain of the CD40 molecule.
  • CD40 also called TNFRSF5
  • hCD40 human CD40
  • the sequence of human CD40 (hCD40) may be found in Uniprot under accession number P25942. It comprises 277 amino acids. The fragment comprising amino acids 216-277 of said sequence is the cytosolic part. Said fragment corresponds to SEQ ID NO:6.
  • the intracellular signaling domain comprises a CD40 cytotail which is a fragment of human CD40.
  • the intracellular signaling domain comprises the amino acid sequence KKVAKKPTNKAPHPKQEPQEINFPDDLPGSNTAAPVQETLHGCQPVTQEDGKESRISVQ ERQ (SEQ ID NO:6).
  • Said first intracellular signaling domain is fused, at its C-terminal end, to a second intracellular signaling domain comprising the CD3zeta intracellular domain.
  • Preferably said fusion is directly performed, i.e. without any linker.
  • CD3zeta also called OKT3 or CD247
  • TCR T cell receptor
  • the TCR in 95% of T cells the TCR consists of an alpha chain and a beta chain, whereas in 5% of T cells the TCR consists of gamma and delta chains.
  • the TCR chains alpha and beta associate with six additional adaptor proteins to form an octameric complex.
  • Said complex comprises both alpha and beta chains, forming the ligand-binding site, but also one CD3gamma chain, one CD3delta chain, two CD3epsilon chains and two CD3zeta chains.
  • the sequence of human CD3zeta chain (hCD3zeta) may be found in Uniprot under accession number P20963. It comprises 164 amino acids.
  • the fragment comprising amino acids 52-164 of said sequence is the cytosolic part. Said fragment corresponds to SEQ ID NO:7.
  • the second intracellular signaling domain comprises the human CD3zeta intracellular domain.
  • the second intracellular signaling domain comprises the amino sequence RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEG LYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO:7).
  • the intracellular signaling domain is either a first intracellular signaling domain comprising the CD40 cytoplasmic tail, preferably of sequence SEQ ID NO:6, or a first intracellular signaling domain comprising the CD40 cytoplasmic tail, preferably of sequence SEQ ID NO:6, which is fused to a second intracellular signaling domain comprising the CD3zeta intracellular domain, preferably of sequence SEQ ID NO:7.
  • the modified cell of the invention is a myeloid cell and comprises a first vector comprising a sequence coding for IL-2 under the control of an inducible or constitutive promoter, and a second vector comprising a sequence coding for a chimeric antigen receptor (CAR), wherein said CAR comprises:
  • an intracellular signaling domain comprising STING or one of its fragments.
  • Said cell is called “modified myeloid cell with a CAR including STING or one of its fragments” in the present application.
  • modified myeloid cell expressing a CAR except the intracellular signaling domain, also apply to the modified myeloid cell with a CAR including STING or one of its fragments.
  • the modified myeloid cell according to the invention comprises a first vector (“CAR2bands”) comprising a sequence coding for IL-2 under the control of an inducible or constitutive promoter, and a sequence coding for a chimeric antigen receptor (CAR) under the control of an inducible or constitutive promoter, wherein said CAR comprises:
  • TEE tumor microenvironment
  • an intracellular signaling domain comprising STING or one of its fragments.
  • the CAR2bands comprises the CAR with its promoter downstream the sequence coding for IL-2 under the control of an inducible or constitutive promoter.
  • the CAR2bands comprises the CAR with its promoter in 3’ of the sequence coding for IL-2 under the control of an inducible or constitutive promoter.
  • the intracellular signaling domain of the modified myeloid cell with a CAR including STING or one of its fragments comprises STING or one of its fragments.
  • STING INterferon Genes
  • ER endoplasmic reticulum
  • STING is an adaptor protein that orchestrates transcriptional activation of type I interferons and inflammatory cytokines in the presence of pathological nucleic acid species.
  • STING activation relies on the detection of dsDNA, ssDNA, or RNA:DNA hybrids by the cyclic GMP-AMP synthetase (cGAS) pathogen recognition receptor. Association of cGAS with these nucleic acid species in the cytosol was found to lead to cGAS-dependent synthesis of cyclic GMP-AMP (cGAMP). Interaction of cGAMP with STING activates a pathway that finally leads to the transcription of pro-inflammatory cytokines and type I interferons.
  • cGAMP cyclic GMP-AMP
  • STING The sequence of human STING may be found in Uniprot under accession number A0A2R3XZB7. It comprises 379 amino acids. Preferably, a sequence with some amino acid deletions in the N-terminal end is used. STING may be used in its wild-type version, or in a mutated form to attenuate its activity.
  • a fragment of STING is used, preferably comprising deletions of the N- terminal end.
  • the fragment corresponds to amino acids 137 to 379 of A0A2R3XZB7.
  • the intracellular signaling domain comprises the amino sequence KGLAPAEISAVCEKGNFNVAHGLAWSYYIGYLRLILPELQARIRTYNQHYNNLLRGAVSQ RLYILLPLDCGVPDNLSMADPNIRFLDKLPQQTGDRAGIKDRVYSNSIYELLENGQRAGT CVLEYATPLQTLFAMSQYSQAGFSREDRLEQAKLFCRTLEDILADAPESQNNCRLIAYQE PADDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAVPSTSTMSQEPELLISGMEKPLPLRT DFS (SEQ ID NO:8).
  • the intracellular signaling domain is encoded by the nucleic sequence SEQ ID NO:10.
  • the present invention further relates to a modified cell comprising a CAR, wherein said CAR comprises:
  • an intracellular signaling domain comprising a chimeric fragment of STING; and wherein said modified cell is a myeloid cell.
  • a chimeric fragment of STING it is meant a modified STING C-terminal tail (CTT).
  • CTT C-terminal tail
  • Said modified STING CTT contains two sequence motifs known as IRF3 and TBK1 and, optionally, an additional fish-specific NF-KB motif.
  • said modified STING CTT is a chimera construct where IRF3 motif is from human STING, and TBK1 and NF-KB motifs are from human STING or fish STING.
  • the fish STING is a zebrafish STING.
  • said modified STING CTT is a chimera construct where IRF3 and TBK1 motifs are from human STING and the NF-KB is from zebrafish STING (said CAR is called “CAR- STINGtz”).
  • CAR-STINGtz comprises the amino sequence: KGLAPAEISAVCEKGNFNVAHGLAWSYYIGYLRLILPELQARIRTYNQHYNNLLRGAVSQ RLYILLPLDCGVPDNLSMADPNIRFLDKLPQQTGDRAGIKDRVYSNSIYELLENGQRAGT CVLEYATPLQTLFAMSQYSQAGFSREDRLEQAKLFCRTLEDILADAPESQNNCRLIAYQE PADDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAVPSTSTMSQEPELLISGMEKPLPLRT DPVETTDYFNPSSAMKQN (SEQ ID NO:1 1 ).
  • CAR-STINGtz is encoded by the following nucleic sequence: AAGGGCCTGGCCCCAGCTGAGATCTCTGCAGTGTGTGAAAAAGGGAATTTCAACGT GGCCCATGGGCTGGCATGGTCATATTACATCGGATATCTGCGGCTGATCCTGCCAG AGCTCCAGGCCCGGATTCGAACTTACAATCAGCATTACAACAACCTGCTACGGGGTG CAGTGAGCCAGCGGCTGTATATTCTCCTCCCATTGGACTGTGGGGTGCCTGATAACC TGAGTATGGCTGACCCCAACATTCGCTTCCTGGATAAACTGCCCCAGCAGACCGGTG ACCGTGCTGGCATCAAGGATCGGGTTTACAGCAACAGCATCTATGAGCTTCTGGAGA ACGGGCAGCGGGCACCTGTGTCCTGGAGTACGCCACCCCCTTGCAGACTTT GTTTGCCATGTCACAATACAGTCAAGCTGGCTTTAGCCGGGAGGATAGGCTTGAGCA GGACACTTGAG
  • the CAR comprises, from its N-terminal end to its C-terminal end:
  • the CAR comprises, from its N-terminal end to its C-terminal end:
  • the CAR comprises, from its N-terminal end to its C-terminal end:
  • targeted effector activity it is meant at least one effector activity chosen from phagocytosis, targeted cellular cytotoxicity, production of cytokines, production of reactive oxygen species (ROS), myeloid activation, antigen processing and presentation to T cells, and in vivo capacity in NSG mice complemented with human T cells to induce human antigen-dependent tumor regression.
  • the targeted effector activity is selected from antigen-dependent phagocytosis of tumor cells, antigen-dependent tumor cell cytokine secretion, and in vivo capacity in NSG mice complemented with human T cells to induce human antigen-dependent tumor regression.
  • Said human antigen-dependent tumor regression is probably mediated by both macrophage phagocytosis of tumor cells and tumor specific T cell killing of tumor cells.
  • Antigen-dependent phagocytosis of tumor cells and antigen-dependent tumor cell cytokine secretion may be measured according to methods well-known in the art, which are illustrated in the examples.
  • In vivo capacity in NSG mice complemented with human T cells to induce human antigen-dependent tumor regression is evaluated according to the protocol described in the examples.
  • All the above embodiments for the second vector are also applicable to the modified cell expressing an interleukin (different from IL-2).
  • the sequence of the interleukin to be expressed is introduced into the first vector instead of the sequence coding for IL-2.
  • the invention also relates to a modified cell expressing at least one cytokine, preferably an interleukin, wherein the cell is chosen from myeloid cells, induced pluripotent stem cells (iPS) and hematopoietic stem cells (HSC), and wherein the cell comprises a first vector comprising a sequence coding for said cytokine under the control of an inducible or constitutive promoter, and optionally a second vector comprising a sequence coding for a CAR, wherein said CAR comprises at least the CD40 cytotail as intracellular signaling domain.
  • said modified cell is preferably a macrophage.
  • the invention also relates to a modified cell expressing at least one interleukin chosen from IL-2, IL-10, IL-15, IL-13, IL-7A, IFNalpha, IFNbeta, IFNIambda, IFNgamma, IL-1 A, IL-1 B, IL-12 and IL-21 , wherein the cell is chosen from myeloid cells, induced pluripotent stem cells (iPS) and hematopoietic stem cells (HSC), and wherein the cell comprises a first vector comprising a sequence coding for said interleukin under the control of an inducible or constitutive promoter, and optionally a second vector comprising a sequence coding for a CAR, wherein said CAR comprises at least the CD40 cytotail as intracellular signaling domain.
  • said modified cell is preferably a macrophage.
  • the present invention also relates to the nucleic acid sequence coding for a CAR according to the invention.
  • Said nucleic acid sequence may be a DNA or RNA sequence.
  • Said nucleic acid sequence may be used in therapy, especially for treating a cancer, an autoimmune disease or an inflammatory disease.
  • said nucleic acid sequence is administered to a subject, preferably by injection.
  • the macrophages of said subject receive said nucleic acid sequence, and subsequently express the CAR, notably the CAR including STING or one of its fragments, preferably the CAR-STINGtz.
  • the nucleic sequence coding for the intracellular domain of said CAR- STINGtz is the sequence SEQ ID NO:12.
  • the nucleic sequence comprises the sequence SEQ ID NO:12.
  • the present invention also relates to the use of a modified myeloid cell, a modified iPS or a modified HSC according to the invention, as a medicament.
  • the present invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a modified myeloid cell, a modified iPS or a modified HSC according to the invention, and a pharmaceutical acceptable carrier.
  • the present invention also relates to the use of the modified myeloid cell, the modified iPS or the modified HSC according to the invention, or of the pharmaceutical composition described above, in the treatment of cancer, an autoimmune disease or an inflammatory disease.
  • the inflammatory disease may be an autoimmune disease.
  • the myeloid cells are obtained from a blood sample of the treated patient (treated donor).
  • they are modified and reinjected to the patient (donor), i.e. they are autologous.
  • autologous means that the modified myeloid cells or the therapeutic composition comprising the modified myeloid cells are used as a treatment for the patient from which the myeloid cells are originated.
  • the present invention also relates to products containing a modified myeloid cell, a modified iPS or a modified HSC according to the invention, and a CAR-T cell, as a combined preparation for simultaneous, separate or sequential use in treatment of cancer, an autoimmune disease or an inflammatory disease.
  • CAR-T cells are well-known in the art.
  • CAR-T cells are chosen from tisagenlecleucel, axicabtagene ciloleucel, brexucabtagene autoleucel, lisocabtagene maraleucel and idecabtagene vicleucel.
  • the present invention also relates to products containing a modified myeloid cell, a modified iPS or a modified HSC according to the invention, and an Immune Checkpoint Inhibitor (ICI) as a combined preparation for simultaneous, separate or sequential use in treatment of cancer, an autoimmune disease or an inflammatory disease.
  • ICI Immune Checkpoint Inhibitor
  • an “immune checkpoint inhibitor” refers to any compound inhibiting the function of an immune checkpoint protein. Inhibition includes reduction of function and full blockade.
  • the immune checkpoint protein is a human immune checkpoint protein.
  • the immune checkpoint protein inhibitor is preferably an inhibitor of a human immune checkpoint protein.
  • Immune checkpoint proteins that may be quoted are CTLA-4, PD-1 , PD-L1 , PD-L2, LAG-3, BTLA, B7H3, B7H4, TIM3, KIR (such as KIR3DL2, KIR2DL1/2/3, KIR2L3), TIGIT, VISTA, IDO, CEACAM-1 or A2aR.
  • KIR such as KIR3DL2, KIR2DL1/2/3, KIR2L3
  • the immune checkpoint inhibitors may be drugs such as small molecules, recombinant forms of ligand or receptors, or preferably antibodies, such as human antibodies.
  • Known inhibitors of the immune checkpoint proteins or analogs thereof may be used, in particular chimerized, humanized or human forms of antibodies.
  • the ICI is selected from an inhibitor of CTLA-4, PD-1 , PD-L1 , PD-L2, LAG- 3, BTLA, B7H3, B7H4, TIM3, KIR (such as KIR3DL2, KIR2DL1/2/3, KIR2L3), TIGIT, VISTA, IDO, CEACAM-1 or A2aR.
  • the ICI is an anti-CTLA-4 antibody, more preferably tremelimumab or ipilimumab.
  • the ICI is an anti-killer-cell immunoglobulin- like receptor (KIR) antibody, more preferably lirilumab and IPH4102.
  • the ICI is an anti-PD-1 antibody, more preferably chosen from nivolumab (ONO-4538, BMS-936558, MDX1106, GTPL7335 or Opdivo), pembrolizumab (MK-3475, MK03475, lambrolizumab, SCH-900475 or Keytruda), pidilizumab, AMP-514, cemiplimab (REGN2810), CT-01 1 , BMS 936559, MPDL3280A, AMP-224, tislelizumab (BGB-A317), spartalizumab (PDR001 or PDR-001), ABBV-181 , JNJ-63723283, Bl 754091 , MAG012, TSR-042, AGEN2034 and antibodies described in International patent applications W02004004771 , W02004056875, W02006121 168, WO2008156712, W02009014708, W020091 14335,
  • the inhibitor of PD-L1 is durvalumab, atezolizumab, LY3300054 or avelumab.
  • the inhibitor of PD-L2 is rHlgM12B7.
  • the LAG3 inhibitor is IMP321 , BMS-986016 or inhibitors of the LAG3 receptor described in US patent US5,773,578.
  • the inhibitor of A2aR is PBF-509.
  • the inhibitor of CTLA-4 is an anti-CTLA-4 antibodies including, but not limited to, ipilimumab (see, e.g., US patents US6,984,720 and US8, 017,1 14), tremelimumab (see, e.g., US patents US7, 109,003 and US8,143,379), single chain anti-CTLA4 antibodies (see, e.g., International patent applications WO1997020574 and W02007123737) and antibodies described in US patent US8,491 ,895.
  • Example of anti-VISTA antibodies are described in US patent application US20130177557.
  • the ICI is chosen from tremelimumab, ipilimumab, lirilumab, nivolumab, pembrolizumab, pidilizumab, AMP-514, REGN2810, CT- 01 1 , BMS 936559, MPDL3280A, AMP-224, durvalumab, atezolizumab, avelumab, rHlgM12B7, IMP321 , BMS-986016 and PBF-509.
  • the present invention also relates to products containing the modified myeloid cell, the modified iPS or the modified HSC according to the invention, and an immune checkpoint therapy related to co-stimulatory antibodies delivering positive signals through immune- regulatory receptors including but not limited to ICOS, CD137, CD27, OX-40 and GITR, as a combined preparation for simultaneous, separate or sequential use in treatment of cancer, an autoimmune disease or an inflammatory disease.
  • an immune checkpoint therapy related to co-stimulatory antibodies delivering positive signals through immune- regulatory receptors including but not limited to ICOS, CD137, CD27, OX-40 and GITR, as a combined preparation for simultaneous, separate or sequential use in treatment of cancer, an autoimmune disease or an inflammatory disease.
  • the present invention also relates to products containing the modified myeloid cell, the modified iPS or the modified HSC according to the invention, and additional cancer therapies as a combined preparation for simultaneous, separate or sequential use in treatment of cancer.
  • products containing the modified myeloid cell, the modified iPS or the modified HSC according to the invention may be administered in combination with targeted therapy, immunotherapy such as immune checkpoint therapy and/or immune checkpoint inhibitor, co-stimulatory antibodies, chemotherapy and/or radiotherapy.
  • the products containing the modified myeloid cell, the modified iPS or the modified HSC according to the invention may be used in combination with targeted therapy.
  • targeted therapy refers to targeted therapy agents, drugs designed to interfere with specific molecules necessary for tumor growth and progression.
  • targeted therapy agents such as therapeutic monoclonal antibodies target specific antigens found on the cell surface, such as transmembrane receptors or extracellular growth factors.
  • Small molecules can penetrate the cell membrane to interact with targets inside a cell. Small molecules are usually designed to interfere with the enzymatic activity of the target protein such as for example proteasome inhibitor, tyrosine kinase or cyclin-dependent kinase inhibitor, histone deacetylase inhibitor.
  • T argeted therapy may also use cytokines.
  • cytokines include: Ado- trastuzumab emtansine (HER2), Afatinib (EGFR (HER1/ERBB1 ), HER2), Aldesleukin (Proleukin), alectinib (ALK), Alemtuzumab (CD52), axitinib (kit, PDGFRbeta, VEGFR1/2/3), Belimumab (BAFF), Belinostat (HDAC), Bevacizumab (VEGF ligand), Blinatumomab (CD19/CD3), bortezomib (proteasome), Brentuximab vedotin (CD30), bosutinib (ABL), brigatinib (ALK), cabozantinib (FLT3, KIT, MET, RET, VEGFR2), Canakinumab (IL-1 beta), carfilzomib (
  • the products containing the modified myeloid cell, the modified iPS or the modified HSC according to the invention may be used in combination with chemotherapy.
  • chemotherapy or “chemotherapy” has its general meaning in the art and refers to a cancer therapeutic treatment using chemical or biochemical substances, in particular using one or several antineoplastic agents or chemotherapeutic agents.
  • Chemotherapeutic agents include, but are not limited to alkylating agents such as thiotepa and cyclosphosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethiylenethiophosphoramide and trimethylolomelamine; acetogenins (especially bullatacin and bullatacinone); a camptothecin (including the synthetic analogue topotecan); bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatin; du
  • calicheamicin especially calicheamicin gammall and calicheamicin omegall
  • dynemicin including dynemicin A
  • bisphosphonates such as clodronate
  • an esperamicin as well as neocarzinostatin chromophore and related chromoprotein enediyne antiobiotic chromophores, aclacinomysins, actinomycin, authrarnycin, azaserine, bleomycins, cactinomycin, carabicin, caminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6- diazo-5-oxo-L-norleucine, doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxy doxor
  • the products containing the modified myeloid cell, the modified iPS or the modified HSC according to the invention is administered to the patient in combination with radiotherapy for simultaneous, separate or sequential use in treatment of cancer, an autoimmune disease or an inflammatory disease.
  • radiation therapies include external beam radiotherapy (such as superficial X-rays therapy, orthovoltage X-rays therapy, megavoltage X-rays therapy, radiosurgery, stereotactic radiation therapy, Fractionated stereotactic radiation therapy, cobalt therapy, electron therapy, fast neutron therapy, neutron-capture therapy, proton therapy, intensity modulated radiation therapy (IMRT), 3-dimensional conformal radiation therapy (3D-CRT) and the like); brachytherapy; unsealed source radiotherapy; tomotherapy; and the like.
  • IMRT intensity modulated radiation therapy
  • 3D-CRT 3-dimensional conformal radiation therapy
  • Gamma rays are another form of photons used in radiotherapy. Gamma rays are produced spontaneously as certain elements (such as radium, uranium, and cobalt 60) release radiation as they decompose, or decay.
  • radiotherapy may be proton radiotherapy or proton minibeam radiation therapy.
  • Proton radiotherapy is an ultra-precise form of radiotherapy that uses proton beams (Prezado Y, Jouvion G, Guardiola C, Gonzalez W, Juchaux M, Bergs J, Nauraye C, Labiod D, De Marzi L, Pouzoulet F, Patriarca A, Dendale R.
  • Radiotherapy may also be FLASH radiotherapy (FLASH-RT) or FLASH proton irradiation.
  • FLASH radiotherapy involves the ultra-fast delivery of radiation treatment at dose rates several orders of magnitude greater than those currently in routine clinical practice (ultra-high dose rate) (Favaudon V, Fouillade C, Vozenin MC. The radiotherapy FLASH to save healthy tissues. Med Sci (Paris) 2015; 31 : 121 -123. DOI: 10.1051/medsci/20153102002); Patriarca A., Fouillade C. M., Martin F., Pouzoulet F., Nauraye C., et al.
  • a first vector comprising a sequence coding for IL-2 under the control of an inducible or constitutive promoter
  • a second vector comprising a nucleic sequence coding for the CAR, preferably a lentiviral vector
  • the invention means tumors.
  • the tumors to be treated include primary tumors and metastatic tumors, as well as refractory tumors.
  • Refractory tumors include tumors that fail to respond or are resistant to treatment with chemotherapeutic agents alone, antibodies alone, radiation alone or combinations thereof.
  • Refractory tumors also encompass tumors that appear to be inhibited by treatment with such agents, but recur up to five years, sometimes up to ten years or longer after treatment is discontinued.
  • cancers that may be treated by the modified myeloid cell according to the invention include, but are not limited to, cancer cells from the bladder, blood, bone, bone marrow, brain, breast, colon, esophagus, gastrointestine, gum, head, kidney, liver, lung, nasopharynx, neck, ovary, prostate, skin, stomach, testis, tongue, or uterus.
  • the cancer may specifically be of the following histological type, though it is not limited to these: neoplasm, malignant; carcinoma; carcinoma, undifferentiated; giant and spindle cell carcinoma; small cell carcinoma; papillary carcinoma; squamous cell carcinoma; lymphoepithelial carcinoma; basal cell carcinoma; pilomatrix carcinoma; transitional cell carcinoma; papillary transitional cell carcinoma; adenocarcinoma; gastrinoma, malignant; cholangiocarcinoma; hepatocellular carcinoma; combined hepatocellular carcinoma and cholangiocarcinoma; trabecular adenocarcinoma; adenoid cystic carcinoma; adenocarcinoma in adenomatous polyp; adenocarcinoma, familial polyposis coli; solid carcinoma; carcinoid tumor, malignant; branchiolo-alveolar adenocarcinoma; papillary adenocarcinoma; chromophobe carcinoma; acid
  • cancer is a solid tumor or a metastasis.
  • autoimmune diseases that may be treated by the modified myeloid cell according to the invention include, but are not limited to, rheumatoid arthritis, inflammatory bowel disease (Crohn disease, ulcerative colitis) or multiple sclerosis.
  • treatment or “treat”, it is meant both prophylactic or preventive treatment as well as curative or disease modifying treatment, including treatment of subjects at risk of contracting the disease or suspected to have contracted the disease as well as subjects who are ill or have been diagnosed as suffering from a disease or medical condition, and includes suppression of clinical relapse.
  • the treatment may be administered to a subject having a medical disorder or who ultimately may acquire the disorder, in order to prevent, cure, delay the onset of, reduce the severity of, or ameliorate one or more symptoms of a disorder or recurring disorder, or in order to prolong the survival of a subject beyond that expected in the absence of such treatment.
  • therapeutic regimen is meant the pattern of treatment of an illness, e.g., the pattern of dosing used during therapy.
  • a therapeutic regimen may include an induction regimen and a maintenance regimen.
  • induction regimen or “induction period” refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the initial treatment of a disease.
  • the general goal of an induction regimen is to provide a high level of drug to a subject during the initial period of a treatment regimen.
  • An induction regimen may employ (in part or in whole) a "loading regimen", which may include administering a greater dose of the drug than a physician would employ during a maintenance regimen, administering a drug more frequently than a physician would administer the drug during a maintenance regimen, or both.
  • maintenance regimen refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the maintenance of a subject during treatment of an illness, e.g., to keep the subject in remission for long periods of time (months or years).
  • a maintenance regimen may employ continuous therapy (e.g., administering a drug at a regular intervals, e.g., weekly, monthly, yearly, etc.) or intermittent therapy (e.g., interrupted treatment, intermittent treatment, treatment at relapse, or treatment upon achievement of a particular predetermined criteria [e.g., disease manifestation, etc.]).
  • a “therapeutically effective amount” it is meant a sufficient amount of the modified myeloid cell, the modified iPS or the modified HSC according to the invention, to treat the disease (e.g. cancer) at a reasonable benefit/risk ratio applicable to any medical treatment.
  • the total daily usage of the product of the present invention will be decided by the attending physician within the scope of sound medical judgment.
  • the specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the product; and like factors well known in the medical arts. For example, it is well known within the skill of the art to start doses of the compound at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.
  • pharmaceutically acceptable carrier or excipient refers to a non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
  • the active principle alone or in combination with another active principle, can be administered in a unit administration form, as a mixture with conventional pharmaceutical supports, to animals and human beings.
  • the pharmaceutical compositions contain vehicles which are pharmaceutically acceptable for a formulation capable of being injected.
  • vehicles which are pharmaceutically acceptable for a formulation capable of being injected.
  • These may be in particular isotonic, sterile, saline solutions (monosodium or disodium phosphate, sodium, potassium, calcium or magnesium chloride and the like or mixtures of such salts), or dry, especially freeze-dried compositions which upon addition, depending on the case, of sterilized water or physiological saline, permit the constitution of injectable solutions.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions; formulations including sesame oil, peanut oil or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
  • the form In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
  • Solutions comprising compounds of the invention as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • the product can be formulated into a composition in a neutral or salt form.
  • Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.
  • inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like.
  • Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine,
  • the carrier can also be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetables oils.
  • the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars or sodium chloride.
  • Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminium monostearate and gelatin.
  • Sterile injectable solutions are prepared by incorporating the active polypeptides in the required amount in the appropriate solvent with several of the other ingredients enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
  • sterile powders for the preparation of sterile injectable solutions
  • the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective.
  • the formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described above, but drug release capsules and the like can also be employed.
  • parenteral administration in an aqueous solution for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
  • sterile aqueous media which can be employed will be known to those of skill in the art in light of the present disclosure.
  • one dosage could be dissolved in 1 ml of isotonic NaCI solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion. Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.
  • the first and/or second vector, or the CAR2bands may be administered via at least one lipid nanoparticle (LNP) or at least one liposome or at least one virus-like particle (VLP).
  • LNPs refer to stable nucleic acid-lipid nanoparticles, particularly in the field of nucleic acid and mRNA drug delivery systems.
  • Liposomes refer to spherical vesicles made of a lipid bilayer.
  • the LNP or liposome comprise at least one ionizable lipid and at least one nucleic acid molecule.
  • the LNP or liposome further comprise at least one helper lipid.
  • the helper lipid is chosen from phospholipids, cholesterol lipids, and polymers.
  • the phospholipid may typically be chosen from dioleoyl-phosphatidylethanolamine (DOPE) or a derivative thereof, distearoylphosphatidylcholine (DSPC) or a derivative thereof, distearoyl-phosphatidylethanolamine (DSPE) or a derivative thereof, stearoyloleoylphosphatidylcholine (SOPC) or a derivative thereof, 1 -stearioyl-2-oleoyl- phosphatidyethanol amine (SOPE) or a derivative thereof, N-(2,3-dioleoyloxy)propyl)- N,N,N-trimethylammonium chloride (DOTAP) or a derivative thereof, or any combination thereof.
  • DOPE dioleoyl-phosphatidylethanolamine
  • DSPC distearoylphosphatidylcholine
  • SOPC stearoyloleoylphosphatidylcholine
  • the cholesterol lipid may be cholesterol or a derivative thereof.
  • the polymer may be polyethylene glycol (PEG) or a derivative thereof.
  • the nucleic acid molecule is a DNA molecule or an RNA molecule.
  • the nucleic acid molecule is cDNA, mRNA, miRNA, siRNA, sgRNA, modified RNA, antagomir, antisense molecule, guide RNA molecule, CRISPR guide RNA molecule, peptide, therapeutic peptide, targeted nucleic acid, or any combination thereof.
  • the liposome is a ligand-targeted liposome which surface is functionalized with at least one target ligand.
  • Said target ligand may be chosen from antibodies, agonist peptides and aptamers. It allows a precise delivery of the first and/or second vector(s) to specific cells such as myeloid cells, preferably monocytes or macrophages, by recognizing corresponding receptors or antigens.
  • VLP Virus-like particles
  • Said VLP can package nucleic acid sequences corresponding to transcription units encoding the CAR and, optionally, transcription units encoding the at least one cytokine, preferably at least one interleukin.
  • the present invention also relates to a method of delivering at least one mRNA molecule encoding the first and/or second vector, or the CAR2bands to a subject in need thereof.
  • the LNP or the composition thereof delivers the mRNA molecule encoding the first and/or second vector, or the CAR2bands to a target, preferably myeloid cells.
  • Said method may comprise a single administration or multiple administrations of the LNP or the composition thereof.
  • the LNP or the composition thereof is administered by a delivery route selected from the group consisting of intradermal, subcutaneous, intramuscular, intraventricular, intrathecal, oral delivery, intravenous, intratracheal, intraperitoneal, in utero delivery, or any combination thereof.
  • the present invention also relates to a method for manufacturing a modified myeloid cell, a modified iPS or a modified HSC, wherein the method comprises:
  • a first vector preferably a lentiviral vector, comprising a nucleic sequence coding for IL-2 or a nucleic sequence coding for at least one interleukin chosen from IL-10, IL-15, IL-13, IL-7A, IFNalpha, IFNbeta, IFNIambda, IFNgamma, IL-1 A, IL-1 B, IL-12 and IL-21 , under the control of an inducible or constitutive promoter; and optionally, a second vector, preferably a lentiviral vector, comprising a sequence coding for a CAR.
  • a first vector preferably a lentiviral vector, comprising a nucleic sequence coding for IL-2 or a nucleic sequence coding for at least one interleukin chosen from IL-10, IL-15, IL-13, IL-7A, IFNalpha, IFNbeta, IFNIambda, IFNgamma, IL-1 A, IL-1 B
  • Said CAR comprises:
  • the first intracellular signaling domain comprising the CD40 cytotail, which is fused to a second intracellular signaling domain comprising the CD3zeta intracellular domain.
  • the first step of the preparation method is the provision of at least one cell chosen from isolated myeloid cells, iPS or HSC.
  • said cells are transduced with at least a first vector, preferably lentiviral vectors, comprising a sequence coding for IL-2 under the control of an inducible or constitutive promoter.
  • the first vector may be used to introduce IL-2 into an isolated myeloid cell, preferably a monocyte.
  • said cells are transduced with two vectors, preferably lentiviral vectors, the first one comprising a sequence coding for IL-2 under the control of an inducible or constitutive promoter, and the second one comprising a nucleic sequence coding for a CAR.
  • the vectors may be used to introduce the CAR and IL-2 into an isolated myeloid cell, preferably a monocyte.
  • said cells may be transduced with a single vector (i.e. first vector) comprising a sequence coding for IL-2 under the control of an inducible or constitutive promoter, and a nucleic sequence coding for a CAR under the control of a promoter.
  • first vector comprising a sequence coding for IL-2 under the control of an inducible or constitutive promoter, and a nucleic sequence coding for a CAR under the control of a promoter.
  • the vector is a plasmid vector, a viral vector, a retrotransposon (e.g. piggyback, sleeping beauty) or a site directed insertion vector (e.g. CRISPR, Zn finger nucleases, TALEN).
  • the vector is a viral vector, preferably a lentiviral vector.
  • Vectors including those derived from retroviruses such as lentivirus, are suitable tools to achieve long-term gene transfer since they allow long-term, stable integration of a transgene and its propagation in daughter cells.
  • Lentiviral vectors have the added advantage over vectors derived from onco-retroviruses, such as murine leukemia viruses, in that they can transduce non-proliferating cells. They also have the added advantage of resulting in low immunogenicity in the subject into which they are introduced.
  • the expression of natural or synthetic nucleic acids is typically achieved by operably linking a nucleic acid to a promoter, and incorporating the construct into an expression vector.
  • the vector is one generally capable of replication in a mammalian cell, and/or also capable of integration into the cellular genome of the mammal.
  • Typical vectors contain transcription and translation terminators, initiation sequences and promoters useful for regulation of the expression of the desired nucleic acid sequence.
  • nucleic sequence (nucleic acid) coding for said CAR or said IL-2 can be cloned into any number of different types of vectors.
  • the nucleic acid can be cloned into a vector including, but not limited to a plasmid, a phagemid, a phage derivative, an animal virus or a cosmid.
  • Vectors of particular interest include expression vectors, replication vectors, probe generation vectors and sequencing vectors.
  • the expression vector may be provided to a cell in the form of a viral vector.
  • Viral vector technology is well known in the art and is described, for example, in Sambrook et al., 2012, MOLECULAR CLONING: A LABORATORY MANUAL, volumes 1 -4, Cold Spring Harbor Press, NY).
  • Viruses which are useful as vectors include retroviruses, adenoviruses, adeno-associated viruses, herpes viruses and lentiviruses.
  • a suitable vector contains an origin of replication functional in at least one organism, a promoter sequence, convenient restriction endonuclease sites, and one or more selectable markers. Additional promoter elements, e.g., enhancers, regulate the frequency of transcriptional initiation. Depending on the promoter, it appears that individual elements can function either cooperatively or independently to activate transcription.
  • the vector is a recombinant lentiviral vector with modified tropism comprising (i) a mutant glycoprotein (G protein) which ablates the natural receptor tropism and (ii) an insertion of an antibody, a receptor ligand or a peptide targeting specifically a cell, preferably a myeloid cell, preferably a monocyte or a macrophage.
  • G protein plays a critical role during the initial steps of virus infection as it is responsible for virus attachment to specific receptors. After binding, G triggers the fusion between the viral and endosomal membranes, which releases the viral genome in the cytosol for the subsequent steps of infection.
  • said recombinant lentiviral vector comprising a mutant G protein allows for an antigen-specific infection of myeloid cells, preferably of monocytes or macrophages.
  • the expression vector to be introduced into a cell can also contain either a selectable marker gene or a reporter gene or both to facilitate identification and selection of expressing cells from the population of cells sought to be transfected or infected through viral vectors.
  • the selectable marker may be carried on a separate piece of DNA and used in a co-transfection procedure.
  • Both selectable markers and reporter genes may be flanked with appropriate regulatory sequences to enable expression in the host cells.
  • Useful selectable markers include, for example, antibiotic-resistance genes, such as neo and the like. Reporter genes are used for identifying potentially transfected cells and for evaluating the functionality of regulatory sequences.
  • a reporter gene is a gene that is not present in or expressed by the recipient organism or tissue and that encodes a polypeptide whose expression is manifested by some easily detectable property, e.g., enzymatic activity. Expression of the reporter gene is assessed at a suitable time after the DNA has been introduced into the recipient cells.
  • Suitable reporter genes may include genes encoding luciferase, beta-galactosidase, chloramphenicol acetyl transferase, secreted alkaline phosphatase, or the green fluorescent protein gene. Suitable expression systems are well known and may be prepared using known techniques or obtained commercially.
  • the construct with the minimal 5' flanking region showing the highest level of expression of reporter gene is identified as the promoter. Such promoter regions may be linked to a reporter gene and used to evaluate agents for the ability to modulate promoter- driven transcription.
  • the method comprises introducing into said cell a first vector, said vector comprising a sequence coding for IL-2 under the control of a cytokine specific promoter.
  • a cytokine specific promoter is chosen from promoter of interleukin-6 or the promoter of interleukin-8.
  • the gene of IL-2 is a human gene of nucleic sequence SEQ ID NO:1 .
  • the method comprises introducing into said cell a second vector, said vector comprising a CAR.
  • the CAR comprises, from its N-terminal end to its C- terminal end:
  • A. STAT5 phosphorylation detected by flow cytometry in different T cell subsets after 10 min of contact with supernatant (SN), or (B) with recombinant human IL-2 (hlL-2) mean +/- SD. N 3 donors.
  • T C on V CD3 + CD4 + CD25' FoxP3‘.
  • T reg CD3 + CD4 + CD25 + FoxP3 + .
  • mice were injected s.c. with 5 10 6 MDA-MB-231 CD19 + GFP + cells. Half of the mice were injected i.v. with CD14- PBMCs (equivalent to 7. 10 6 cells). Mice were left untreated or injected intra-tumorally (i.t.) with IL-2-Mono or control monocytes.
  • B Body weight measured over 35 days.
  • C Tumor size measured with a caliper over 35 days.
  • Figure 4 Flow cytometry analyses of the spleen and tumors from mice having received cellular therapies
  • mice from the experiment depicted in Fig 3 were sacrificed at day 35 post tumor injection. Their spleen and remaining tumor were harvested, stained for the indicated markers, and analyzed by flow cytometry to determine the fraction of human cells and tumor cells present in these preparations. % of CD3+ cells were not represented for mice with less than 1% of CD45+ cells.
  • Purified CD14+ cells were transduced with lentivectors encoding the indicated CAR constructs, cultured for 6 days in the presence of M-CSF, and without any antibiotic selection.
  • 10 3 MDA-MB-231 cells (MDA-GFP-CD19) were seeded in Ultra-Low Attachment 96-well plates, resulting in the formation of tumor spheroids growing in 3D.
  • 2.10 3 untransduced macrophages (UTD) or CAR-macrophage (CAR-STOP, CAR-CD3z or CAR-STINGtz) were added to established spheroids.
  • GFP intensity representing spheroid growth of MDA-GFP-CD19 tumor cells was followed by time-lapse microscopy every 3h for 168h. The means of GFP intensity calculated from spheroids in triplicates +/- SD are displayed.
  • Purified CD14+ cells were transduced with lentivectors encoding the indicated CAR constructs cultured for 6 days in the presence of M-CSF and without any antibiotic selection. Macrophages were recovered and seeded alone or with A549 tumor cells expressing CD19+ or not for 24h. Quantification of cytokines was performed by Legendplex in the supernatant of the indicated co-cultures. Untransduced (UTD) macrophages or macrophages transduced with CAR-STOP, CAR-CD3z or CAR-STINGtz were cultured with media alone (0), A549 or A549-CD19+ cells, at a 1 :1 E:T ratio for 24h. Each dot represents one donor.
  • Purified CD14+ cells were transduced with lentivectors encoding the indicated CAR2bands construct, cultured for 3 days in the presence of M-CSF and without any antibiotic selection. Macrophages were recovered and seeded alone or with A549 tumor cells expressing CD19+ or not for 24h. Quantification of the indicated cytokines was performed by CBA in the supernatant of the indicated co-cultures. Untransduced (UTD) macrophages or macrophages transduced with IL2-STOP or IL2-STING were cultured with media alone (no tumor), A549 or A549-CD19+ cells. CAR Macrophages were cultured at a 1 :1 E:T ratio for 24h. Each dot represents one donor.
  • Example 1 Engineering autologous monocytes expressing IL-2 and/or CAR-
  • MDA-MB-231 human breast adenocarcinoma cell line was maintained in RPMI complete medium (GibcoTM Roswell Park Memorial Institute 1640 complemented with 10% fetal calf serum and 1 % GibcoTM Penicillin-Streptomycin (Thermofischer)).
  • HEK 293 FT cells were maintained in DMEM complete medium (GibcoTM Dulbecco's Modified Eagle Medium complemented with 10% fetal calf serum and 1% Penicillin-Streptomycin).
  • MDA-MB-231 -GFP and MDA-MB-231 -GFP-CD19 were obtained by lentiviral transduction with pWPXLd-GFP coding for GFP and with pCDH1 -CD19 coding for hCD19.
  • Transduced cell lines were FACS sorted to obtain homogenous cell populations.
  • PBMC Peripheral blood mononuclear cells
  • Ficoll-Paque Ficoll-Paque
  • Monocytes were isolated by CD14 + positive selection using CD14magnetic microbeads (Miltenyi 130-050-201 ) and CD3+ T cells by negative selection using (Miltenyi 130-096-535).
  • CAR constructs and human IL-2 (hlL-2) were cloned into pCDH1 lentiviral vector containing a puromycin resistance gene under the control of an EF1a promoter.
  • Lentivirus were produced in HEK293 FT cells. Lentiviral vectors were co transfected with psPAX2 (2nd generation lentiviral packaging plasmid) and pMD2.G (encoding VSV-G) using PEI MAX® (Polysciences). Vpx-VLPs were produced in HEK293FT cells by transfection of pSIV3 and pMD2.G (S. Bobadilla et al., 2013)
  • CD14 + cells were transduced with lentivectors in presence of Vpx-VLPs and 4pg/mL protamine. Monocytes were then allowed to differentiate in macrophages for 10 days in macrophage medium (RPMI + 5% fetal calf serum + 5% human serum + 1 % Penicillinstreptomycin) with 50ng/mL M-CSF in Corning® 100 mm Not TC-treated Culture Dish.
  • macrophage medium RPMI + 5% fetal calf serum + 5% human serum + 1 % Penicillinstreptomycin
  • 1 x10 5 CAR Macrophages were co-cultured with 1 x10 5 A549-GFP or A549-GFP-CD19 cells for 3h at 37°C.
  • Cells were harvested with Accutase and stained with anti-CD45- Alexa700 (Biolegend) antibody in presence of FcBlockTM (BD Biosciences) and analyzed with FACS using a Bio-Rad ZE5. The percent of GFP+ events within the CD45+ population was plotted as the percentage of phagocytosis.
  • Human primary T cells were isolated from PBMC with Pan T Cell Isolation Kit human (Miltenyi Biotec). 200 000 T cells were put in contact with cells, supernatants or recombinant human IL-2 for 10 min before being fixed with paraformaldehyde 2%. Cells were permeabilized by methanol, marked with antibodies (anti-CD3-PECy7, anti-CD4-APCCy7, anti-CD25-PE, anti-FoxP3-Alexa488, anti-pSTAT5-Alexa647) and analyzed with BD FACSVerseTM flow cytometer.
  • PBMCs Human primary monocytes purified from PBMCs were transduced with a lentiviral vector encoding IL-2 under the control of the constitutive CMV promoter. After 7 days of culture in the presence of monocyte colony-stimulating factor (M-CSF), the supernatant was replaced by fresh medium. 3 days later the macrophages were harvested. Cell expression of IL-2 was assayed by intracellular flow cytometry with an anti-IL-2-PE antibody after cell permeabilization. While macrophages untransduced or transduced with a control vector did not express IL-2, the great majority (more than 90%) of macrophages transduced with IL- 2 (IL-2-M ) expressed IL-2 ( Figure 1 A).
  • M-CSF monocyte colony-stimulating factor
  • the supernatant of the IL-2-M0 cultured for 3 days contained 300 ng/ml fo IL-2 +/- 150ng/ml, as measured by CBA ( Figure 1 B).
  • IL-2 concentration was measured in the supernatant of monocytes as a function of time posttransduction.
  • IL-2- transduced monocytes secreted detectable levels IL-2 as soon as 3 days post transduction ( Figure 1 C).
  • IL-2 produced by IL-2-M0 is functionally active on primary T lymphocytes
  • the inventors assayed the functionality of the IL-2 produced by IL-2-M0 by measuring the IL-2-induced phosphorylation of STAT5 that initiates the signaling cascade leading to T cell survival and proliferation.
  • the supernatant of IL-2-M0 was incubated with human primary T cells for 10 min before fixation, permeabilization of the cells, and staining with an antibody specific for phosphorylated ST AT5.
  • Total CD3+ T cells freshly purified from PBMC isolated from healthy donors were used in this assay.
  • STAT5 phosphorylation was measured in three T cell subsets: CD4 + T conv (conventional T cells, defined as CD3+ CD4+, CD25- Foxp3-), Treg (regulatory T cells, defined as CD3+ CD4+, CD25+, Foxp3+) and CD8 + T cells (defined as CD3+ CD4-), because they express the IL-2R at different levels, the high affinity IL-2R being mainly expressed by Treg at the steady state. Only the supernatant of IL-2-M triggered the phosphorylation of STAT5 in all populations of T cells to various extents: Treg > T conv > CD8 T cells in agreement with their respective expression of IL- 2R chains ( Figure 2A).
  • the inventors also assessed the potential of IL-2-I more directly, by plating them for 24h before directly adding primary T cells for 10 min (Figure 2C). Different ratios of macrophages to T cells were tested, giving rise to nice dose effect curves. The presence of macrophages did not impair the capacity of secreted IL-2 to phosphorylate STAT5 in a dosedependent manner similarly to hlL-2. Together, our data show that IL-2-I secrete substantial amounts of IL-2 that are capable to activate all populations of primary T cells.
  • MDA-MB-231 GFP + CD19 + cells were injected by the subcutaneous route into immunodeficient NSG mice. Half of the mice received at day 10 an intravenous (iv) injection of monocytes-depleted PBMCs (CD14- cells). The proportion of CD3 + T cells present in the CD14- fraction was estimated by flow cytometry and the number of CD14- cells injected was adjusted to contain 7.10 6 CD3 + T cells.
  • mice received an intratumoral (i.t.) injection of either 10.10 6 of IL-2-transduced monocytes (Mono-IL-2) or the same number or monocytes transduced with an empty vector (control monocytes).
  • IL-2-transduced monocytes IL-2-transduced monocytes
  • control monocytes the same number or monocytes transduced with an empty vector.
  • the monocytes were transduced in vitro at day 10, left overnight in the incubator and injected it at day 1 1 , i.e. less than 24h after being purified and transduced.
  • the inventors concluded that transduction of monocytes with IL-2 encoding vector results in cells able to induce tumor regression in immunodeficient mice partially reconstituted with T cells.
  • injection of Mono-IL-2 and CD14- cells induces in NSG Mice carrying a human tumor an efficient graft versus tumor reaction.
  • mice from the experiments described in Fig 3 were sacrificed at day 35 post tumor injection, their spleen and remaining tumor were harvested, stained, and analyzed by flow cytometry (Figure 4). Human myeloid cells remained undetectable using a CD64 specific Ab at both locations. Nevertheless, mice injected with Mono-IL-2 contained high levels of human CD45+ cells which were in majority CD3 + T cells. Of note, the purity of our monocyte preparations were regularly higher than 98% (not shown), indicating that in the group of mice which only received Mono-IL-2 the very few contaminating T cells were probably efficiently expended with the help of the IL-2 produced by the Mono-IL-2 (see panel A in the tumor the % of CD3+ T cells).
  • CAR-M0 CAR-macrophage
  • MDA-MB-231 cells expressing GFP and CD19 MDA-GFP- CD19
  • UTD untransduced macrophages
  • CAR-M0 CAR-STOP, CAR- CD3z or CAR-STINGtz
  • Spheroids growth is measured by live cell imaging using GFP fluorescence ( Figure 5).
  • Antigen stimulation of CAR Macrophages induces secretion of proinflammatory cytokines and interferons
  • CAR-M0 CAR-macrophage
  • IL12 (IL- 12p70) is essential for T cell priming, GM-CSF promotes myeloid cell survival and activates macrophages, IFNalpha (IFN-a2) and beta (IFN-b) are essential to elicit a robust anti-tumor response locally.
  • IFNalpha IFNalpha
  • beta IFN-b
  • IL-1 IL-1 b
  • IL-6 activate T cells but are antagonistic to Treg cells.
  • IL- 10 production reflects macrophage activation.
  • TNFalpha (TNF-a) enhances phagocytosis.
  • the CAR-STINGtz macrophages according to the invention allows to activate, upon CD19+ antigen binding, both the IRF3 and NF-KB pathways, stimulating the production of several cytokines. Importantly, in the absence of the tumor antigen, almost no cytokines are released by the CAR macrophages.
  • the structure of the CAR2bands vector is in Figure 7. Untransduced (UTD) macrophages or CAR2bands macrophages transduced with IL2-STOP or IL2-STING were cultured with media alone (no tumor), A549 or A549-CD19+ cells and cytokines in the supernatant were quantified ( Figure 8).
  • the inventors concluded that macrophages expressing the CAR2bands IL2-STING can produce substantial amounts of IP10 when put in contact with CD19+ expressing cells, revealing that activation of their CAR containing a truncation of STING leads to type I IFN production, which in turn induces the expression of interferon- stimulated genes such as IP10. Moreover, activation of STING also leads to the activation of the minimal promoter driving the expression of the payload IL2. Substantial amounts of IL2 are thus produced in response to antigen exposure.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une cellule modifiée comprenant un transgène codant pour l'interleukine 2 (IL-2). Ladite cellule modifiée comprend un premier vecteur comprenant une séquence codant pour l'IL-2 sous le contrôle d'un promoteur inductible ou constitutif, qui permet notamment une expression contenue localement d'IL-2. L'invention concerne également des utilisations thérapeutiques de celles-ci.
PCT/EP2023/076524 2022-09-26 2023-09-26 Cellules myéloïdes exprimant l'il-2 et leurs utilisations pour une thérapie anticancéreuse rapide WO2024068617A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22306417.1 2022-09-26
EP22306417 2022-09-26

Publications (1)

Publication Number Publication Date
WO2024068617A1 true WO2024068617A1 (fr) 2024-04-04

Family

ID=83691427

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/076524 WO2024068617A1 (fr) 2022-09-26 2023-09-26 Cellules myéloïdes exprimant l'il-2 et leurs utilisations pour une thérapie anticancéreuse rapide

Country Status (1)

Country Link
WO (1) WO2024068617A1 (fr)

Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020574A1 (fr) 1995-12-04 1997-06-12 The Regents Of The University Of California Blocage de la retro-regulation de lymphocytes t associee a la signalisation par ctla-4
WO1998015294A1 (fr) * 1996-10-09 1998-04-16 Oxford Biomedica (Uk) Limited Phagocytes mononucleaires utilises dans l'apport de medicament therapeutique
US5773578A (en) 1990-01-08 1998-06-30 Institut National De La Sante Et De La Recherche Medicale Proteins produced by human lymphocytes, DNA sequence encoding these proteins and their pharmaceutical and biological use
WO2004004771A1 (fr) 2002-07-03 2004-01-15 Ono Pharmaceutical Co., Ltd. Compositions immunostimulantes
WO2004056875A1 (fr) 2002-12-23 2004-07-08 Wyeth Anticorps anti pd-1 et utilisations
US6984720B1 (en) 1999-08-24 2006-01-10 Medarex, Inc. Human CTLA-4 antibodies
CN1261160C (zh) * 2004-08-05 2006-06-28 深圳市奥克生物技术有限公司 杂交酵母艾滋病疫苗
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
WO2006121168A1 (fr) 2005-05-09 2006-11-16 Ono Pharmaceutical Co., Ltd. Anticorps monoclonaux humains pour mort programmee 1 (mp-1) et procedes pour traiter le cancer en utilisant des anticorps anti-mp-1 seuls ou associes a d’autres immunotherapies
WO2007123737A2 (fr) 2006-03-30 2007-11-01 University Of California Procédés et compositions de sécrétion localisée d'anticorps anti-ctla-4
WO2008156712A1 (fr) 2007-06-18 2008-12-24 N. V. Organon Anticorps dirigés contre le récepteur humain de mort programmée pd-1
WO2009014708A2 (fr) 2007-07-23 2009-01-29 Cell Genesys, Inc. Anticorps pd-1 en combinaison avec une cellule sécrétant de la cytokine et leurs procédés d'utilisation
WO2009114335A2 (fr) 2008-03-12 2009-09-17 Merck & Co., Inc. Protéines de liaison avec pd-1
US8017114B2 (en) 1999-08-24 2011-09-13 Medarex, Inc. Human CTLA-4 antibodies and their uses
WO2013043569A1 (fr) 2011-09-20 2013-03-28 Vical Incorporated Immunothérapie combinée à action antitumorale synergique faisant appel à des alloantigènes
US20130177557A1 (en) 2010-03-26 2013-07-11 Randolph J. Noelle Vista regulatory t cell mediator protein, vista binding agents and use thereof
WO2014047350A1 (fr) 2012-09-20 2014-03-27 Morningside Technology Ventures Ltd. Virus oncolytique codant pour des agents de liaison de pd-1 et ses utilisations
WO2018193119A1 (fr) * 2017-04-21 2018-10-25 Ospedale San Raffaele S.R.L. Thérapie génique
WO2020160217A1 (fr) * 2019-02-01 2020-08-06 Seattle Children's Hospital (dba Seattle Children's Research Institute) Capteurs de microenvironnement pour réguler l'expression génique modifiée
WO2021011919A1 (fr) * 2019-07-17 2021-01-21 Fate Therapeutics, Inc. Ingénierie de cellules effectrices immunitaires et utilisation de celles-ci
WO2021062281A2 (fr) * 2019-09-25 2021-04-01 Fate Therapeutics, Inc. Cellules effectrices à ciblage multiple et leur utilisation

Patent Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773578A (en) 1990-01-08 1998-06-30 Institut National De La Sante Et De La Recherche Medicale Proteins produced by human lymphocytes, DNA sequence encoding these proteins and their pharmaceutical and biological use
WO1997020574A1 (fr) 1995-12-04 1997-06-12 The Regents Of The University Of California Blocage de la retro-regulation de lymphocytes t associee a la signalisation par ctla-4
WO1998015294A1 (fr) * 1996-10-09 1998-04-16 Oxford Biomedica (Uk) Limited Phagocytes mononucleaires utilises dans l'apport de medicament therapeutique
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US8143379B2 (en) 1998-12-23 2012-03-27 Amgen Fremont Inc. Human monoclonal antibodies to CTLA-4
US8491895B2 (en) 1998-12-23 2013-07-23 Amgen Fremont Inc. Methods of treating cancer with human monoclonal antibodies to CTLA-4
US6984720B1 (en) 1999-08-24 2006-01-10 Medarex, Inc. Human CTLA-4 antibodies
US8017114B2 (en) 1999-08-24 2011-09-13 Medarex, Inc. Human CTLA-4 antibodies and their uses
WO2004004771A1 (fr) 2002-07-03 2004-01-15 Ono Pharmaceutical Co., Ltd. Compositions immunostimulantes
WO2004056875A1 (fr) 2002-12-23 2004-07-08 Wyeth Anticorps anti pd-1 et utilisations
CN1261160C (zh) * 2004-08-05 2006-06-28 深圳市奥克生物技术有限公司 杂交酵母艾滋病疫苗
WO2006121168A1 (fr) 2005-05-09 2006-11-16 Ono Pharmaceutical Co., Ltd. Anticorps monoclonaux humains pour mort programmee 1 (mp-1) et procedes pour traiter le cancer en utilisant des anticorps anti-mp-1 seuls ou associes a d’autres immunotherapies
WO2007123737A2 (fr) 2006-03-30 2007-11-01 University Of California Procédés et compositions de sécrétion localisée d'anticorps anti-ctla-4
WO2008156712A1 (fr) 2007-06-18 2008-12-24 N. V. Organon Anticorps dirigés contre le récepteur humain de mort programmée pd-1
WO2009014708A2 (fr) 2007-07-23 2009-01-29 Cell Genesys, Inc. Anticorps pd-1 en combinaison avec une cellule sécrétant de la cytokine et leurs procédés d'utilisation
WO2009114335A2 (fr) 2008-03-12 2009-09-17 Merck & Co., Inc. Protéines de liaison avec pd-1
US20130177557A1 (en) 2010-03-26 2013-07-11 Randolph J. Noelle Vista regulatory t cell mediator protein, vista binding agents and use thereof
WO2013043569A1 (fr) 2011-09-20 2013-03-28 Vical Incorporated Immunothérapie combinée à action antitumorale synergique faisant appel à des alloantigènes
WO2014047350A1 (fr) 2012-09-20 2014-03-27 Morningside Technology Ventures Ltd. Virus oncolytique codant pour des agents de liaison de pd-1 et ses utilisations
WO2018193119A1 (fr) * 2017-04-21 2018-10-25 Ospedale San Raffaele S.R.L. Thérapie génique
WO2020160217A1 (fr) * 2019-02-01 2020-08-06 Seattle Children's Hospital (dba Seattle Children's Research Institute) Capteurs de microenvironnement pour réguler l'expression génique modifiée
WO2021011919A1 (fr) * 2019-07-17 2021-01-21 Fate Therapeutics, Inc. Ingénierie de cellules effectrices immunitaires et utilisation de celles-ci
WO2021062281A2 (fr) * 2019-09-25 2021-04-01 Fate Therapeutics, Inc. Cellules effectrices à ciblage multiple et leur utilisation

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BREMPELIS KATHERINE J ET AL: "Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 8, no. 2, 1 October 2020 (2020-10-01), GB, pages e001356, XP093116052, ISSN: 2051-1426, DOI: 10.1136/jitc-2020-001356 *
FAVAUDON VFOUILLADE CVOZENIN MC: "The radiotherapy FLASH to save healthy tissues", MED SCI (PARIS, vol. 31, 2015, pages 121 - 123
GIULIA ESCOBAR ET AL: "Interferon gene therapy reprograms the leukemia microenvironment inducing protective immunity to multiple tumor antigens", NATURE COMMUNICATIONS, vol. 9, no. 1, 24 July 2018 (2018-07-24), XP055639214, DOI: 10.1038/s41467-018-05315-0 *
KLICHINSKY MICHAEL ET AL: "Human chimeric antigen receptor macrophages for cancer immunotherapy", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP US, NEW YORK, vol. 38, no. 8, 23 March 2020 (2020-03-23), pages 947 - 953, XP037211712, ISSN: 1087-0156, [retrieved on 20200323], DOI: 10.1038/S41587-020-0462-Y *
PATRIARCA A.FOUILLADE C. M.MARTIN F.POUZOULET F.NAURAYE C. ET AL.: "Experimental set-up for FLASH proton irradiation of small animals using a clinical system", INT J RADIAT ONCOL BIOL PHYS, vol. 102, 2018, pages 619 - 626, XP085474451, DOI: 10.1016/j.ijrobp.2018.06.403
PIERINI STEFANO ET AL: "Chimeric antigen receptor macrophages (CAR-M) induce antitumor immunity and synergize with T cell checkpoint inhibitors in pre-clinical solid tumor models", AACR ANNUAL MEETING 2021, 9 April 2021 (2021-04-09), XP093116602, Retrieved from the Internet <URL:https://74dfcf.p3cdn1.secureserver.net/wp-content/uploads/2021/09/AACR21_Pierini.pdf> [retrieved on 20240108] *
PREZADO YJOUVION GGUARDIOLA CGONZALEZ WJUCHAUX MBERGS JNAURAYE CLABIOD DDE MARZI LPOUZOULET F: "Tumor Control in RG2 Glioma-Bearing Rats: A Comparison Between Proton Minibeam Therapy and Standard Proton Therapy", INT J RADIAT ONCOL BIOL PHYS., vol. 104, no. 2, 1 June 2019 (2019-06-01), pages 266 - 271
PREZADO YJOUVION GPATRIARCA ANAURAYE CGUARDIOLA CJUCHAUX MLAMIRAULT CLABIOD DJOURDAIN LSEBRIE C: "Proton minibeam radiation therapy widens the therapeutic index for high-grade gliomas", SCI REP., vol. 8, no. 1, 7 November 2018 (2018-11-07), pages 16479
RAMOS ET AL., CELL, vol. 185, 2022, pages 1 - 19
SAMBROOK ET AL.: "MOLECULAR CLONING: A LABORATORY MANUAL", vol. 1-4, 2012, COLD SPRING HARBOR PRESS

Similar Documents

Publication Publication Date Title
US11826384B2 (en) Genetic engineering of macrophages for immunotherapy
US20210179687A1 (en) Targeting lilrb4 with car-t or car-nk cells in the treatment of cancer
US20230051406A1 (en) Genetically modified natural killer cells and methods of use thereof
US20230304031A1 (en) Vectors and methods for in vivo transduction
EP4062920A1 (fr) Médicament pour le traitement du cancer, association médicamenteuse, composition de médicament, cellule immunitaire réactive, véhicule d&#39;administration d&#39;acides nucléiques et produit
US20220162288A1 (en) Cellular therapeutics engineered with signal modulators and methods of use thereof
US20230060351A1 (en) A method of engineering natural killer cells to target cd70-positive tumors
US20220378739A1 (en) Natural killer cell immunotherapy for the treatment of glioblastoma and other cancers
WO2024068617A1 (fr) Cellules myéloïdes exprimant l&#39;il-2 et leurs utilisations pour une thérapie anticancéreuse rapide
WO2023194608A1 (fr) Cellules myéloïdes modifiées par un récepteur antigénique chimérique et leurs utilisations pour une thérapie anticancéreuse
WO2023194607A1 (fr) Cellules myéloïdes modifiées par un récepteur antigénique chimérique avec cd40 et leurs utilisations pour une thérapie anticancéreuse
US20230285558A1 (en) Engineered t cells and tumor-infiltrating lymphocytes to increase tumor killing
CA3234457A1 (fr) Cellules tueuses naturelles et leurs methodes d&#39;utilisation
Valia Emerging Natural Killer Cell Immunotherapy for Acute Myeloid Leukemia
WO2023107898A1 (fr) Ciblage double de malignités pédiatriques par cellules car-t sécrétant des activateurs de cellules immunitaires innés bispécifiques (bices)
WO2023187024A1 (fr) Protéine rela modifiée pour induire l&#39;expression d&#39;interféron et cellules immunitaires modifiées ayant une expression d&#39;interféron améliorée
WO2023211972A1 (fr) Lymphocytes t régulateurs modifiés par un récepteur antigénique chimérique pour le traitement du cancer
WO2020092696A1 (fr) Activation et expansion ex vivo de lymphocytes t pour une thérapie par transfert adoptif de cellules

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23777258

Country of ref document: EP

Kind code of ref document: A1